Shattuck Labs

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Why Levi Strauss Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027.

Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline

Earnings

Penny Stocks

Analyst Ratings

Trading Ideas

KYMR

Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares ended the last trading session 23.4% higher at $39.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock&#39;s 6.7% loss over the past four weeks.

Kymera Therapeutics Surges 23.4%: Is This an Indication of Further Gains?

Shattuck Labs Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming December Conferences

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Agenus

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

bluebird bio

Celularity

Dyadic International, Inc. - Common Stock

Dyadic International

Fortress Biotech

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Lantern Pharma

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Rein Therapeutics

Repare Therapeutics

Skye Bioscience

Spero Therapeutics

Xilio Therapeutics

Leerink Partners

Citigroup

BTIG

Comments

Shattuck Labs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga